Antiperspirant composition

Abstract

This document describes antiperspirant compositions comprising an antiperspirant. The antiperspirant comprises optionally substituted benzenepropenoic acid. Optionally substituted benzenepropenoic acid, optionally combined with an ester of gallic acid, is also described. Methods and uses of the antiperspirant compositions and antiperspirants, for example, to reduce or prevent sweating, are also described.

Description

[Technical Field]

[0001] The present invention relates to antiperspirant compositions. The present invention also relates to methods for reducing or preventing sweating, and to the use of certain natural ingredients, particularly plant-derived chemicals, as antiperspirants. [Background technology]

[0002] Antiperspirant compositions are a well-known type of product in the field of personal care, used to eliminate or reduce body odor (important for daily hygiene). These compositions are available in a wide range of forms for administration, such as solid sticks, roll-ons, tissues, aerosol sprays, and pump sprays.

[0003] The composition generally contains an active ingredient (often referred to as an antiperspirant) that narrows or blocks the sweat gland ducts to reduce or prevent sweating. Antiperspirants may also provide a deodorant effect if they can mask odor or provide antibacterial activity.

[0004] Commonly used antiperspirants are aluminum or aluminum-zirconium salts, such as chlorohydroxyaluminum or aluminum zirconium tetrachlorohydrex gly (AZG). These salts dissolve on the skin, block pores, and reduce or prevent sweating. [Overview of the project] [Problems that the invention aims to solve]

[0005] To harmonize or improve the sweat-reducing properties of aluminum or aluminum zirconium salts, investigations are underway into other compounds with similar functions. [Means for solving the problem]

[0006] In a first aspect, the present invention provides an antiperspirant composition comprising an antiperspirant comprising optionally substituted benzenepropenic acid. The optionally substituted benzenepropenic acid is a plant-derived compound.

[0007] A first aspect of the present invention also provides an antiperspirant composition comprising an antiperspirant, wherein the antiperspirant comprises a plant compound which is optionally substituted benzenepropenic acid.

[0008] In a second aspect, the present invention also provides an antiperspirant composition. The antiperspirant composition comprises either (a) a natural extract or (b) an antiperspirant obtained from or derived from a natural extract.

[0009] In the second embodiment, the natural extract is either cinnamon extract or cinnamon extract and amla (Emblica officinalis) extract. The natural extract is preferably cinnamon extract.

[0010] The antiperspirant in (b) may be present in the antiperspirant composition in the form of the natural extract in (a).

[0011] Surprisingly, it has been found that certain types of plant compounds or plant extracts possess antiperspirant properties. These naturally derived substances are used as antiperspirants, particularly in personal care products. They can provide antiperspirant effects comparable to aluminum or aluminum zirconium salts, which are commonly found in commercially available antiperspirant products. Thus, plant compounds or plant extracts are included as antiperspirants in place of aluminum or aluminum zirconium salts. These substances, especially natural extracts, can impart a pleasant scent to antiperspirant compositions. There are no health concerns associated with these ingredients.

[0012] A third aspect of the present invention relates to a method for reducing or preventing sweating. This method comprises applying an antiperspirant composition according to the first or second aspect of the present invention to the skin.

[0013] The third aspect of the present invention also includes the use of an antiperspirant composition for reducing or preventing sweating.

[0014] The fourth aspect of the present invention relates to the use of optionally substituted benzenepropenoic acid for reducing or preventing sweating.

[0015] The fourth aspect includes the use of a phytocompound as an antiperspirant for reducing or preventing sweating, wherein the phytocompound is optionally substituted benzenepropenoic acid.

[0016] The fifth aspect of the present invention relates to the use of a natural extract as an antiperspirant for reducing or preventing sweating. The natural extract in the fifth aspect is cinnamon extract or cinnamon extract and amla extract. It is preferable that the natural extract is cinnamon extract.

Mode for Carrying Out the Invention

[0017] The following definitions apply to this specification (including all aspects of the invention and their specific examples).

[0018] As used herein, the term "personal care" (used alone or in combination with other terms) refers to non-therapeutic uses, such as non-therapeutic, cosmetic uses. This term generally refers to use for personal hygiene.

[0019] The compounds and derivatives described herein are named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service) nomenclature or by their common names. It should also be understood that each mention of a compound described herein (e.g., a polyurea, a primary monoamine, a diamine, or a triamine) encompasses all stereoisomers (e.g., cis and trans isomers) and / or optical isomers (e.g., R and S enantiomers) of such a compound (in substantially pure form or in mixtures of various ratios).

[0020] The term "phytochemicals" as used herein refers to chemical compounds produced by plants (for example, through primary or secondary metabolism). In other words, phytochemicals are naturally occurring, biologically active compounds found in plants. Phytochemicals generally possess biological activity that protects plants from the environment, diseases, or predators.

[0021] The term "flavonoid" as used herein refers to a compound having a 15-carbon core structure (e.g., a skeleton) consisting of two phenyl rings (called rings A and B) and a heterocycle containing an oxygen atom (called the C ring). The term "flavonoid" is used in the conventional, limited sense to refer only to compounds having a C6-C3-C6 carbon framework (e.g., core structure or skeleton) with the structure of chroman or 1-benzopyran (chromene) (where the fused benzene ring is represented as ring A, and 3,4-dihydro-2H-pyran or pyran is represented only as the C ring (along with the phenyl group on the C ring (ring B)) (see, for example, AP Rauter et al. "Nomenclature of Flavonoids" (Reference 1)). A general structure of a flavonoid (with the rings labeled) is shown below. [ka]

[0022] Depending on the position of ring B's attachment to the chroman / 1-benzopyran (chromene) moiety, the term "flavonoid" may include or consist of subclasses of compounds known as 2-flavonoids, 3-flavonoids (e.g., known as isoflavonoids), and 4-flavonoids (e.g., also known as neoflavonoids).

[0023] The term "2-flavonoid" used here is given by formula (A-1) [ka] This refers to a compound having a core structure or skeleton represented by [the given symbol].

[0024] In formula (A-1), the atoms in the core structure are numbered according to the IUPAC numbering scheme for this subclass of the compound.

[0025] To avoid misunderstanding, formula (A-1) represents the core structure or skeleton of a 2-flavonoid. Rings A-C of the core structure may contain substituents. Ring C may contain a carbon-carbon double bond (in addition to the unsaturation arising from the fusion phenyl group (ring A)) and / or a carbonyl group.

[0026] Generally, the term "2-flavonoid" includes flavans, flavones, or flavanols.

[0027] If the ring C in formula (A-1) does not contain a carbon-carbon double bond or a carbonyl group, then formula (A-1) represents a flavan. The term "flavan" refers to a compound having a 2-phenyl-3,4-dihydro-2H-1-benzopyran skeleton.

[0028] In formula (A-1), if ring C is substituted with a hydroxyl group, for example at the 3- or 4-position of ring C, then the 2-flavonoid is a flavanol.

[0029] The core structure or skeleton of flavanols is flavan-3-ol (represented by formula (A-2)), flavan-4-ol (represented by formula (A-3)), and flavan-3,4-diol (represented by formula (A-4)): Formula (A-2) [ka] , Formula (A-3) [ka] , Formula (A-4) [ka] .

[0030] If the ring C in formula (A-1) contains a carbonyl group (for example, the compound is derived from a 2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one skeleton), then the 2-flavonoid is a flavanone, in particular a flavan-4-one (for example, represented by formula (A-5)): Formula (A-5) [ka] .

[0031] It is preferable that the core structure or skeleton of the 2-flavonoid is not an anthocyanidin (also known as anthocyanin). Anthocyanidins are flavilium (2-phenyl-1λ 4 It is a compound derived from the -benzopyran-1-illium or 2-phenylchromenylium) ion.

[0032] The term "glucogallin" used here refers to the following compound: [ka] . Glucogalin is generally found in amla extract. Thus, glucogalin is obtained from or can be obtained from alam extract.

[0033] The terms "sea buckthorn" or "sea buckthorn extract" used herein are synonymous with arum or arum extract, respectively, and refer to the fruit or fruit extract of arum (synonymous with eucalyptus emblica), and more commonly known as amla berry or Indian gooseberry.

[0034] As used by itself or in combination with other terms, “substituted” means that a hydrogen atom on a molecule has been replaced by a different atom or atom group. The atom or atom group that replaces a hydrogen atom is a “substituent.” The terms “substituent,” “part,” and “group” (including plural forms) should be understood to mean “substituent” (including plural forms).

[0035] The various hydrocarbon-containing parts shown here are prefixes indicating the minimum and maximum number of carbon atoms in the part, i.e., "C a -C b It is written using ". For example, C a -C b Alkyl refers to an alkyl group having an integer number of carbon atoms, from a to b.

[0036] As used herein, the term “alkyl” (used alone or in combination with other terms) refers to a branched or unbranched saturated hydrocarbon chain, unless otherwise specified. Unless otherwise indicated, alkyl groups are generally unsubstituted. Alkyl groups have 1 to 6 carbon atoms, for example, 1 to 4 carbon atoms. Typical examples include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, and n-hexyl.

[0037] As used here, the term "alkoxy" refers to an alkyloxy group (where alkyl groups are already defined). Unless otherwise specified, alkoxy groups are generally unsubstituted. Typical examples include -Ome, -OEt, and -O n Pr, -O i It includes Pr.

[0038] The term "deodorant" as used herein refers to an agent, substance, or composition that masks or inhibits the formation of unpleasant body odor.

[0039] The amount of a substance (e.g., a compound), composition, or component is generally defined as a mass percentage of the composition.

[0040] When used with measurable values, the term "approximately" includes, for example, a reasonable range of values ​​to allow for experimental error in the measurement of the said value.

[0041] As used herein, the term "contains" has a broad meaning that allows for the presence of other unspecified features. This term encompasses the semi-open term "essentially consists of" and the closed term "consists of." Unless the context indicates otherwise, the term "contains" may be replaced with either "essentially consists of" or "consists of." The term "essentially consists of" may also be replaced with "consists of."

[0042] To avoid misunderstanding, the expression "essentially consisting of" used herein limits the scope of the feature to include the specific substance and other substances or processes that do not substantially affect the fundamental and novel properties of the feature, such as trace amounts of impurities. The expression "essentially consisting of" encompasses the expression "~consisting of". antiperspirant

[0043] This invention relates to the use of naturally derived or obtained products as antiperspirants.

[0044] Antiperspirants are used to reduce or prevent sweating. Thus, antiperspirants are the active ingredients in the antiperspirant composition of the present invention for reducing or preventing sweating.

[0045] Sweating is a physiological bodily function that helps regulate and maintain body temperature at approximately 37°C. Sweat is produced by sweat glands, which are skin appendages composed of an outer layer of myoepithelial contractile cells and an inner layer of secretory cells. When body temperature rises, sweat glands are activated by signals sent from the brain to produce sweat. In addition to maintaining stable body temperature, sweat moisturizes the skin and releases toxins. Excessive sweating can cause unpleasant odors, such as body odor and other ailments.

[0046] The antiperspirant functions by limiting the amount of sweat released by the skin through the ducts of the sweat glands by forming a buffer.

[0047] The antiperspirant of the present invention is for external use (for example, on the human body).

[0048] The antiperspirant composition or antiperspirant is one that is applied to the surface of the body, particularly the skin.

[0049] The antiperspirant comprises an optionally substituted benzenepropenoic acid. The antiperspirant may essentially consist of an optionally substituted benzenepropenoic acid.

[0050] For all aspects of the present invention, here, the antiperspirant is further described by the following numbered clauses: 1. The antiperspirant comprises an optionally substituted benzenepropenoic acid or essentially consists of an optionally substituted benzenepropenoic acid. 2. In the antiperspirant according to clause 1, the optionally substituted benzenepropenoic acid is trans-benzenepropenoic acid. 3. In the antiperspirant according to clause 2, the optionally substituted benzenepropenoic acid is of formula (I)

Chemical formula

[0051] The antiperspirant in any of the above items 1 to 31 may be present in the antiperspirant composition in the form of a natural extract (in the second aspect of the present invention).

[0052] In all aspects of the present invention, the natural extracts are further described by the following numbered sections: 32. The natural extract is cinnamon extract and optionally amla extract, for example, a mixture of cinnamon extract and amla extract. Preferably, the natural extract is cinnamon extract (for example, cinnamon extract only). 33. In the natural extracts described in item 32, the cinnamon extract comprises one or more 2-flavonoids. 34. In the natural extract described in item 33, at least one of the one or more 2-flavonoids is a flavanol, preferably a flavan-3-ol. 35. In the natural extracts described in Section 34, flavanol or flavan-3-ol is afzerekin, epiafzerekin, catechin, epicatechin, gallocatechin, epigallocatechin, or a combination of two or more thereof. 36. In any of the natural extracts described in paragraphs 33 to 35, at least one of the 1 or more 2-flavonoids is a flavanone, preferably a flavan-4-one. 37. In the natural extracts described in item 36, flavanone or flavan-4-one is rutin. 38. In any of the natural extracts described in paragraphs 32 to 37, the cinnamon extract comprises cinnamic acid, preferably trans-cinnamic acid. 39. The natural extracts described in item 32 include amla extract. 40. In the natural extracts described in section 32 or 39, the amla extract comprises glucogallin (e.g., β-glucogallin). 41. In any of the natural extracts described in paragraphs 32-40, the natural extract is an antioxidant. 42. In any of the natural extracts described in paragraphs 32 to 41, the natural extract is a protein coagulant. 43. In any of the natural extracts described in paragraphs 32 to 42, the natural extract is a preservative. 44. In any of the natural extracts described in paragraphs 32 to 43, the natural extract is an antibacterial agent.

[0053] While we do not wish to be bound by theory, the antiperspirants of the present invention, whether existing as individual compounds or in the form of natural extracts, can block the pores of sweat glands by causing protein coagulation and / or by binding to specific receptors in the walls of the sweat glands.

[0054] Surprisingly, it was discovered that cinnamic acid has antiperspirant properties. This compound is thought to be capable of causing protein coagulation or aggregation.

[0055] Generally, as measured according to the U.S. Food and Drug Administration guidelines (Reference 3), antiperspirants and / or natural extracts have at least a 20% reduction in sweating in at least 50% of the test subjects. The term "test subjects" is synonymous with "target population" as described in the U.S. Food and Drug Administration guidelines.

[0056] Generally, antiperspirants and / or natural extracts may also be deodorants.

[0057] In addition, antiperspirants and / or natural extracts have an astringent effect, a color-matching effect, and / or an anti-aging effect on the skin, preferably an astringent effect. Antiperspirant composition

[0058] The antiperspirant composition of the present invention comprises an antiperspirant as defined in the preceding heading section, including those defined in any of sections 1 to 31. The antiperspirant may exist as a previously defined natural extract, including those defined in any of sections 32 to 44. The antiperspirant is obtained from or is obtained from a natural extract.

[0059] Generally, an antiperspirant as defined above is a single antiperspirant in an antiperspirant composition.

[0060] If the antiperspirant composition contains a previously defined natural extract, it is preferable that the natural extract is a single antiperspirant.

[0061] Generally, antiperspirant compositions do not contain aluminum chlorohydrate or aluminum zirconium tetrachlorohydrex gly. Preferably, antiperspirant compositions do not contain aluminum-containing antiperspirants, and more preferably, they do not contain aluminum and optionally zirconium.

[0062] In addition, or otherwise, the antiperspirant composition does not contain 4-hydroxybenzaldehyde. The antiperspirant composition contains (i) benzaldehyde or formula I: [ka] (Here, R 1 R is selected from the group consisting of H, CH2, CH3, OH, and OCH3; 2 is selected from the group consisting of H, OH, OCH3, and OCH2O, and R 2 If R is OCH2O, 1 Is it CH2, or R 2 (ii) a benzaldehyde derivative compound that forms a bond with (ii) benzaldehyde, 4-methylbenzaldehyde, heliotropin, vanillin, 4-hydroxybenzaldehyde, 3-hydroxybenzaldehyde, 4-methoxybenzaldehyde, 3-methoxybenzaldehyde, or 3-hydroxy-4-methoxybenzaldehyde (isovanillin).

[0063] An antiperspirant composition contains an effective amount of antiperspirant or natural extract. An effective amount is defined as the amount that reduces or prevents sweating.

[0064] The antiperspirant composition generally comprises an antiperspirant in a total amount of about 0.1 to about 25.0%, preferably about 0.5 to about 15.0% by mass, more preferably about 1.0 to 10.0% by mass, for example, about 1.0 to about 5.0% by mass.

[0065] The antiperspirant composition generally comprises an antiperspirant in a total amount of about 0.1 to about 4.0% by mass, for example, about 0.5 to about 4.0% by mass, more preferably about 1.0 to 4.0% by mass, for example, about 1.0 to about 3.5% by mass.

[0066] If the antiperspirant comprises optionally substituted benzenepropenoic acid, for example trans-cinnamic acid, or essentially comprises optionally substituted benzenepropenoic acid, for example trans-cinnamic acid, the antiperspirant composition contains optionally substituted benzenepropenoic acid (for example trans-cinnamic acid) in a total amount of about 0.5 to about 25.0% by mass (for example 1.5 to about 25.0% by mass), preferably about 1.0 to about 20.0% by mass (for example about 3.0 to about 20.0% by mass), more preferably about 1.5 to about 15.0% by mass (for example about 5.0 to about 15.0% by mass), for example about 2.0 to about 10.0% by mass.

[0067] The antiperspirant composition generally contains a total of about 5.0 to about 40.0% by mass of natural extracts, preferably about 10.0 to about 30.0% by mass, and more preferably about 15.0 to about 25.0% by mass of natural extracts.

[0068] The amount of natural extract contained in an antiperspirant composition depends on the composition of the extract, particularly the type and amount of components present in the natural extract.

[0069] Generally, antiperspirant compositions refer to cosmetic antiperspirant compositions, particularly cosmetic antiperspirant compositions for personal care.

[0070] Antiperspirant compositions are generally intended for topical use. Thus, an antiperspirant composition may be a topical antiperspirant composition.

[0071] Antiperspirant compositions are applied topically to the skin, preferably to the surface of the skin. Antiperspirant compositions are formulated for specific modes of topical application.

[0072] Generally, antiperspirant compositions consist of a topically acceptable carrier. The topically acceptable carrier depends on the type of formulation and the mode of topical application.

[0073] Locally acceptable carriers are water, alcohol, ether, oil, or wax.

[0074] For example, if the antiperspirant composition is a gel, paste, liquid, lotion, or foam, the locally acceptable carriers are water or water and oil.

[0075] Locally acceptable carriers may be alcohols. These alcohols may be monoalcohols or polyhydric alcohols (e.g., alcohol compounds having two or more hydroxyl groups).

[0076] If the alcohol is a monoalcohol, it is either ethanol or a fatty alcohol. Fatty alcohols have a linear chain length of 6 to 18 carbon atoms. Stearyl alcohol is preferred as the fatty alcohol.

[0077] If the alcohol is a polyhydric alcohol, it is either a polymeric alcohol or a monomeric alcohol. Polymeric alcohols are polyalkylene alcohols (e.g., PEG or PPG). Monomeric alcohols are ethylene glycol, propylene glycol, glycerol, or sugars (e.g., glucose, sorbitol, or xylitol).

[0078] Locally acceptable carriers may be ethers. The ether in question is PPG-14 butyl ether.

[0079] Locally acceptable carriers may include oil. The oil in question is hydrogenated castor oil.

[0080] Antiperspirant compositions are provided or included in deodorants, such as body deodorants for personal hygiene purposes.

[0081] Antiperspirant compositions come in the form of creams, gels, pastes, liquids, lotions, foams, scrubs, and powders.

[0082] Generally, antiperspirant compositions are leave-on compositions. Leave-on compositions are applied to the skin or the surface of the skin, left for a specific period (e.g., from 1 minute to 24 hours), and then wiped off or washed with water (usually during a regular washing process).

[0083] If the antiperspirant composition is in liquid form, the liquid is either a water-in-oil emulsion or an oil-in-water emulsion.

[0084] Generally, if an antiperspirant composition is in liquid form, the liquid is a sprayable liquid.

[0085] The antiperspirant composition may also be delivered as an aerosol. The locally acceptable carrier may contain a pressurized gas.

[0086] The antiperspirant composition may contain a lubricant. Examples of lubricants include cyclomethicone, dimethicone, phenyltrimethicone, or ethylmethicone. The lubricant is preferably cyclomethicone and / or phenyltrimethicone.

[0087] The antiperspirant composition of the present invention may further contain natural oils. The natural oils are included for skincare purposes.

[0088] Generally, natural oils consist of unsaturated lipids, such as polyunsaturated lipids (e.g., triglycerides derived from linolenic acid) and / or monounsaturated lipids (e.g., triglycerides derived from oleic acid).

[0089] The antiperspirant composition may further contain antioxidant components. The antioxidant components are included to chemically stabilize the antiperspirant or various other components that may be present, such as natural oils, particularly natural oils comprising polyunsaturated lipids and / or monounsaturated lipids.

[0090] The antioxidant component is selected from ascorbic acid, butylhydroxytoluene, tetra(di-t-butylhydroxyhydrocinnamate) pentaerythrityl, and tris(tetramethylhydroxypiperidinol) citrate.

[0091] It may contain antiperspirant tatami mat fragrance.

[0092] The antiperspirant composition may contain a thickening agent. The thickening agent is fumed silica or cellulose ether, such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, cetyl hydroxyethyl cellulose, hydroxybutyl methylcellulose, methyl hydroxyethyl cellulose, or xanthan gum. It is preferable that the thickening agent is fumed silica.

[0093] Antiperspirant compositions may contain surfactants. Surfactants can be anionic surfactants, cationic surfactants, nonionic surfactants, or amphoteric surfactants.

[0094] Antiperspirant compositions may contain personal care ingredients. Personal care ingredients are skincare agents, such as emollients, moisturizers, skin barrier enhancers, or skin appearance improvers.

[0095] The antiperspirant composition may contain a wide range of other optional ingredients, such as binders, biological additives, buffering agents, pigments, fragrances, conditioners, exfoliants, pH adjusters, preservatives, skin smoothing agents, or skin healing agents.

[0096] The antiperspirant composition preferably comprises a preservative and optionally one or more components selected from binders, biological additives, buffering agents, pigments, fragrances, conditioners, exfoliants, pH adjusters, preservatives, skin smoothing agents, and skin healing agents.

[0097] Generally, antiperspirant compositions, as measured according to U.S. Food and Drug Administration guidelines (Reference 3), exhibit at least a 20% reduction in sweating in at least 50% of test subjects.

[0098] Generally speaking, antiperspirant compositions are also deodorant compositions.

[0099] Antiperspirant compositions are manufactured by general methods known in the art. Method and Use

[0100] The method or use of the present invention is non-therapeutic.

[0101] The antiperspirant composition of the present invention is particularly intended for use as a cosmetic for personal care.

[0102] The antiperspirant composition or antiperspirant is applied to the skin, preferably topically.

[0103] Antiperspirant compositions or antiperspirants are applied to the surface of the skin.

[0104] Generally speaking, skin refers to mammalian skin, preferably human skin.

[0105] Generally, antiperspirant compositions or antiperspirants are applied to areas of skin where sweating occurs, preferably areas of skin where sweat glands are present, such as apocrine sweat glands or eccrine sweat glands, preferably areas of skin where apocrine sweat glands are present.

[0106] The areas of skin include the thighs (e.g., inner thighs), groin, back, upper lip, armpits, knees (e.g., back of the knees), neck (e.g., back of the neck), buttocks, chest, scalp, or hands. The armpits are preferred as the area of ​​skin.

[0107] Antiperspirant compositions or antiperspirants are applied by applicators that come into direct contact with the body, such as roll-on lotions or solid stick products.

[0108] Alternatively, the antiperspirant composition or antiperspirant may be applied by a non-contact applicator, such as by spraying it onto the skin. Non-contact applicators include aerosol sprays, pump sprays, and squeeze sprays.

[0109] Antiperspirants, natural extracts, and / or antiperspirant compositions may be intended for use as deodorants. Examples

[0110] Next, the invention will be described in detail by the following non-limiting embodiments. [Examples 1-3]

[0111] The prescription examples 1-3 shown in Table 1 were prepared using general methods. [Table 1]

[0112] In Table 1: E1 is cinnamon extract; E2 is amla extract; and E3 is trans-cinnamic acid. The extracts were obtained from Sabinsa Corporation. Each natural extract is included in each formulation in an amount that provides the same amount of antiperspirant throughout the formulation. [Comparative Example]

[0113] To provide a comparison with the formulations in Table 1, the formulations shown in the table were prepared. These formulations do not contain natural extracts. [Table 2]

[0114] In Table 2, AP1 is aluminum chlorohydrate, and AP2 is aluminum zirconium tetrachlorohydrex glycine (AZG). Roll-on antiperspirant products

[0115] The method for manufacturing roll-on products is shown below. 1. Mix cyclomethicone, phenyl trimethicone, stearyl alcohol, butyl ether, and hydrogenated castor oil. Heat to 2.82°C to melt the solid. 3. While maintaining a temperature of 82°C, slowly add fumed silica using a high-speed disc-type dispenser. 4. After adding all the silica, increase the mixing rate to a peripheral speed of approximately 4000 ft / min or more to achieve satisfactory dispersion. 5. Add starch, followed by natural AP powder. 6. Before adding the next component, it is important to ensure that each component is evenly dispersed. 7. After adding all the ingredients, cool the mixture to 55°C. In vivo testing procedure Test design

[0116] The formulation was tested in a standard hot-room assessment clinical study. After applying the antiperspirant composition, research panelists were subjected to heat stress. The reduction in sweat was measured by sweat weight collection.

[0117] Target: 40 female panelists

[0118] Condition: 17-day washout period (during which time the panelists did not use any antiperspirants).

[0119] Test design: Participants were subjected to a 5-day application period, and each participant was given one of the example prescriptions in the form of 400 mg + 50 mg. After the 5th day, panelists were placed in a hot room (38°C ± 1°C (100°F ± 2°F) and relative humidity 35% ± 5%) for 80 minutes to increase sweating, and then the sweat was collected.

[0120] Data Analysis: Data were converted to natural logarithms, and the mean values ​​were analyzed according to the method described by Murphy and Levine (Reference 2). The covariance model analysis included factors for sequencing, subjects in the sequence, test substance, axilla, and baseline as covariates.

[0121] The percentage change in sweat reduction was measured for each formulation. Clinical trial data showed that all formulations were effective in reducing sweating, with formulations F1-F3 showing a sweat reduction of 30% or more. A sweat reduction of at least 20% is considered suitable for commercial use as an antiperspirant.

[0122] Formula F3 demonstrated comparable sweating efficacy results when compared to comparative products containing aluminum or aluminum zirconium. [Examples 4 and 5]

[0123] Further experiments were conducted using Formulation 3 (see Table 1 above), except that the amount of trans-cinnamic acid was changed. Formulation 4 contains 3% by mass of trans-cinnamic acid. Formulation 5 contains 10% by mass of trans-cinnamic acid. These formulations were prepared using a similar method to that used to manufacture the roll-on antiperspirant product described above. In vivo testing

[0124] In vivo testing was performed using each prescription.

[0125] For consistency in the study, participants were required to demonstrate an axillary sweat volume of 150 mg at the initial assessment. The same methodology as described above was used to conduct these tests, with the exception of the details below.

[0126] Prescription 4: The trial involved 30 panelists, each of whom was given 400 mg of Prescription 4 during a 5-day application period.

[0127] Prescription 5: The trial involved 33 panelists, each of whom was given Prescription 5 at 400 mg during an 18-day application period.

[0128] In the study, if a pre-treatment record (baseline) exists for the evaluation of axillary sweating after the final application, the proportion of axillae treated with the study product, adjusted for the ratio of sweating rates between the right and left axillaes, is calculated for each individual using the formula: Z = (PC x T) / (PT x C) (In the formula, Z is the ratio adjusted from left to right; PC is the amount of sweat obtained before treatment of the control axilla; PT is the amount of sweat obtained before treatment of the axilla to be treated; T is the amount of sweat obtained for the axilla treated with the formulation of the present invention; and C is the amount of sweat obtained for the control axilla) is defined as follows.

[0129] The results are shown in Tables 3 and 4 below. (Table 3) Prescription 4 TIFF2026521097000013.tif73145 (Table 4) Prescription 5 TIFF2026521097000014.tif67141

[0130] In both trials, no statistically significant difference was observed in median sweating between the product and the control. According to the techniques used to evaluate antiperspirant effects, formulations 4 and 5 showed a reduction in sweating 8 hours after the last application. Both tests indicated that at least 50% of subjects experienced at least a 20% reduction in sweating. [Example 6]

[0131] A study was conducted to evaluate the deodorant effect using Formulation 5. To measure the deodorant efficacy of trans-cinnamic acid, a deodorant efficacy study was designed as a single-center, single-blind, randomized controlled trial.

[0132] In this study, 12 subjects were pre-conditioned by using only soap and refraining from using deodorants, antiperspirants, fragrances, or medicinal products for a minimum of 48 hours, as in the study described above.

[0133] On the test day, participants were evaluated for their odor by three judges. The odor score was measured from 0 (odorless) to 4 (strong). To participate in the test, participants were required to have an odor score of at least 3.

[0134] Immediately after participant evaluation and eligibility check, Formula 5 was applied to one armpit. All subjects were randomized. Then, at 8, 24, and 48 hours, subjects were evaluated for odor.

[0135] In particular, the results from the study showed a statistically significant decrease in odor scores at 8 hours, 24 hours, and 48 hours. reference

[0136] The following documents were referenced in the specification. 1. AP Rauter et al.; "Nomenclature of Flavonoids (IUPAC Recommendation 2017)"; Pure Appl. Chem., 90(9), (2018), 1429-1486. 2. TD Murphy & MJ Levine; "Analysis of the effectiveness tests of antiperspirants"; Journal of the Society of Cosmetic Chemists, 42, (1991), 167-197. 3. When reading in conjunction with § 350.60 (21 CFR 350.60) of the final monograph (final rule) on OTC antiperspirant products published in the U.S. Federal Register dated June 9, 2003 (68 FR 34273), refer to the "Guidelines for Testing OTC Antiperspirant Products" issued by the U.S. FDA.

[0137] The full text of each reference cited herein is incorporated here by reference. All references referenced herein are incorporated here by reference as if each reference had been incorporated individually as a whole by reference.

[0138] The references and incorporations of patent documents in this specification are for convenience only and do not reflect any opinion regarding the validity, patentability, and / or feasibility of such patent documents.

[0139] Numerous specific examples of the invention have been described. Nevertheless, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, other specific examples are also within the scope of the claims.

[0140] All titles and subtitles are used herein for convenience only and should not be understood as limiting the invention in any way.

[0141] Any and all embodiments or illustrative expressions (e.g., “For Example”) presented herein are merely for illustrative purposes and do not imply any limitation on the scope of the invention unless further paragraphs are provided. Expressions in this specification should not be understood as indicating any non-paragraph elements essential for the practice of the invention.

Claims

1. An antiperspirant composition comprising an antiperspirant, wherein the antiperspirant comprises optionally substituted benzenepropenoic acid.

2. The antiperspirant composition according to claim 1, wherein the optionally substituted benzenepropenoic acid is a plant-derived chemical substance.

3. The antiperspirant composition according to claim 1 or 2, wherein the optionally substituted benzenepropenoic acid is trans-benzenepropenoic acid.

4. The optionally substituted benzenepropenoic acid is given by formula (I): 【Chemistry 1】 (Here, R 1 ~R 5 Each of them independently consists of H, hydroxyl, and C. 1 -C 6 An antiperspirant composition according to any one of claims 1 to 3, represented by (selected from alkoxy).

5. R 1 ~R 5 The antiperspirant composition according to claim 4, wherein at least three of the elements are hydrogen.

6. R 1 ~R 5 Two adjacent ones of which are each independently hydroxy and C 1 -C 6 The antiperspirant composition according to claim 4 or 5, selected from alkoxy.

7. R 1 , R 4 , and R 5 is hydrogen, R 2 and R 3 Each of them independently comprises hydroxyl and C 1 -C 6 An antiperspirant composition according to any one of claims 4 to 6, selected from alkoxys.

8. The antiperspirant composition according to any one of claims 1 to 4, wherein the optionally substituted benzenepropenoic acid is selected from cinnamic acid, o-cinnamic acid, m-cinnamic acid, p-cinnamic acid, caffeic acid, ferulic acid, 5-hydroxyferulic acid, and sinapic acid.

9. The antiperspirant composition according to claim 8, wherein the optionally substituted benzenepropenoic acid is trans-cinnamic acid.

10. The antiperspirant composition according to any one of claims 1 to 10, wherein the antiperspirant further comprises an ester of gallic acid.

11. The antiperspirant composition according to claim 10, wherein the ester of gallic acid is selected from flavonoid esters of gallic acid and sugar esters of gallic acid.

12. The antiperspirant composition according to claim 11, wherein the ester of gallic acid is a sugar ester of gallic acid, and preferably the sugar ester of gallic acid is glucogallin (e.g., β-glucogallin).

13. The antiperspirant composition according to any one of claims 1 to 12, wherein the antiperspirant is obtained from or derived from a natural extract, preferably the natural extract being cinnamon extract and optionally amla extract, for example, a mixture of cinnamon extract and alam extract.

14. An antiperspirant composition according to any one of claims 1 to 13, comprising an antiperspirant in a total amount of approximately 0.1 to approximately 25.0% by mass.

15. The antiperspirant composition according to any one of claims 1 to 14, comprising optionally substituted benzenepropenoic acid in a total amount of about 0.5 to 25.0% by mass, preferably 1.5 to about 25.0% by mass, and more preferably about 3.0 to 20.0% by mass.

16. An antiperspirant composition according to any one of claims 1 to 15, which does not contain 4-hydroxybenzaldehyde.

17. An antiperspirant composition comprising cinnamon extract and optionally arum extract, for example, a natural extract which is a mixture of cinnamon extract and arum extract.

18. The antiperspirant composition according to claim 17, wherein the cinnamon extract contains one or more 2-flavonoids.

19. The antiperspirant composition according to claim 18, wherein at least one of the one or more 2-flavonoids is a flavanol, preferably a flavanone-3-ol.

20. The antiperspirant composition according to claim 19, wherein the flavanol or flavan-3-ol is afzerekin, epiafzerekin, catechin, gallocatechin, epigallocatechin, or a combination of two or more thereof.

21. At least one of the 1 or more 2-flavonoids is a flavanone, preferably a flavan-4-one. The antiperspirant composition according to any one of claims 18 to 20.

22. The antiperspirant composition according to claim 21, wherein the flavanone or flavan-4-one is rutin.

23. The antiperspirant composition according to any one of claims 17 to 22, wherein the cinnamon extract comprises cinnamic acid, preferably trans-cinnamic acid.

24. The antiperspirant composition according to any one of claims 17 to 23, wherein the natural extract comprises an arum extract, and the arum extract comprises glucogallin (e.g., β-glucogallin).

25. An antiperspirant composition according to any one of claims 17 to 24, comprising natural extracts in a total amount of approximately 5.0 to 40.0% by mass.

26. Furthermore, the antiperspirant composition according to any one of claims 1 to 25, comprising a locally acceptable carrier.

27. An antiperspirant composition according to any one of claims 1 to 26, which is in the form of a cream, gel, paste, liquid, lotion, foam, scrub, or powder.

28. The antiperspirant composition according to any one of claims 1 to 27, further comprising a lubricant.

29. The antiperspirant composition according to any one of claims 1 to 28, further comprising a fragrance.

30. The antiperspirant composition according to any one of claims 1 to 29, further comprising a thickening agent.

31. The antiperspirant composition according to any one of claims 1 to 30, further comprising a preservative.

32. A method for reducing or preventing sweating, comprising the step of applying an antiperspirant composition according to any one of claims 1 to 31 to the skin.

33. Use of the antiperspirant composition according to any one of claims 1 to 31 for reducing or preventing sweating.

34. Use of optionally substituted benzenepropenoic acid, optionally in combination with an ester of gallic acid, as an antiperspirant for reducing or preventing sweating, wherein the optionally substituted benzenepropenoic acid is as defined in any of claims 2 to 9, and the ester of gallic acid is as defined in any of claims 11 to 13.

35. Use of a natural extract as an antiperspirant for reducing or preventing sweating, wherein the natural extract is cinnamon extract and optionally arum extract, preferably the natural extract is as defined in any of claims 17 to 25.

Images